Consequently, the expression of IL-4 and the nuclear localization of NLRP3 in combination with TOX positivity could have clinical applications as potential prognostic markers, and this mechanism of IL-4/NLRP3/TOX enhancement may provide an effective target in the design of new therapeutic strategies to stop CTCL progression. Here, NLRP3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.